Winning the war on bacteria superbugs: Reversing the trends
(1888PressRelease) A new topical antibiotic formulation, designed to overcome drug resistance
of MRSA, is now available OTC. Known as Tetracycline-ABC, it kills the most drug-resistant
and the most deadly bacteria (Staph, MRSA and Acinetobacter), which cause community or
hospital acquired infections.
(1888PressRelease) Since the discovery of two classes of antibiotics over 70 years ago, penicillin
in 1929 and the first sulfonamide, prontosil, in 1932, the ensuing decades have given rise to a
total of 13 classes of antibiotic, some now in their fifth generation. At the peak of development,
new drugs were coming out at a rate of 15 to 20 every ten years, but in the last ten years, we have
seen only 6 new drugs, according to Medical News Today.
Many pharmaceutical companies are abandoning or scaling back antibiotic research and
development in favor of more profitable drugs that treat chronic conditions. However, a novel
antibiotic design to overcome drug resistance of antibiotics was announced today by Phillips
Company, an FDA-registered Native American owned pharmaceutical manufacturer.
"Our company is a not-for-profit pharmaceutical developer. We are not driven by profits, so we
can focus on what is needed more than what is profitable," said a spokesman for Phillips
Company. The novel formulation uses both physical and chemical mechanisms of action to kill
bacteria. Most existing antibiotics use only a chemical mechanism for effectiveness, resulting in
those drugs becoming less effective over time as bacteria evolve to become more able to survive
the effects of antibiotics.
The novel approach uses an antibiotic formulation designed to enhance physical transport and
physical cell penetration that speeds the active ingredient deep into the cell structure of a wound
where the chemical mechanism of action can be more effective.
Methicillin Resistant Staphylococcus Aureus (MRSA), the most notorious antibiotic-resistant
strain of staph bacteria, has been wreaking havoc throughout communities all over the world.
The CDC announced that there are more people dying of MRSA in the U.S. than of AIDS,
raising it to epidemic proportions. To make matters even worse, some experts are now predicting
that there will be an emergence of new strains of antibiotic-resistant bacteria in the future.
"Our novel approach to overcome drug resistance of antibiotics is designed to sustain the
effectiveness of antibiotics and other topical drugs for many years, giving new topical drug
products a longer useful lifetime and therefore more commercial value," said a spokesman for
Phillips Company. "This technology, when licensed to larger pharmaceutical companies, will
provide stronger incentive for the discovery and development of new antimicrobial drugs. In
recent years, the dearth of new antibiotics has been largely due to the uncertainty of the
commercial life of new drugs which is diminished when bacteria develop an immunity to the
effectiveness of that drug."
The manufacturer believes this is the world's strongest broad-spectrum topical antibiotic. It kills
the most drug-resistant and the most deadly bacteria (Staph, MRSA and Acinetobacter), which
cause community or hospital acquired infections. The new drug was carefully tested on ten of the
most harmful kinds of bacteria and it was found to be the most effective against MRSA, the most
notorious antibiotic-resistant strain of bacteria. The Tetracycline-ABC topical antibiotic kills all
other harmful Gram positive and Gram negative bacteria that have been available for testing.
Tetracycline-ABC will be licensed to a larger company for manufacturing and
commercialization. Phillips Company is a small pharmaceutical development company with
manufacturing capacity limited to 50,000 units per month. Using the develop-and-license
business model, the company licensed six pharmaceutical products in 2010.
Licensing inquiries: http://www.PhillipsCompany.4T.com
Graphs/images (for re-publiction, if desired) are available (not copyrighted, no charge) online at